Related Experiment Video
Updated: May 7, 2026
Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
Published on: December 9, 2010
Nanomedicine And Nanotheranostics: Special Focus on Imaging of Anticancer Drugs Induced Cardiac Toxicity
Aseem Setia1, Randheer Reddy Challa2, Bhaskar Vallamkonda2
1Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi-221005, India.
Abstract:
Cardiotoxicity, the often-overlooked second leading cause of death in cancer patients, has been associated with certain anticancer drugs. These drugs can induce cardiac damage through various pathways, and their adverse effects on the heart are not fully understood. Cardiotoxicity is a major issue in cancer treatment, particularly with chemotherapeutics, because it can cause cardiac dysfunction such as hypotension, heart failure, and even death. Doxorubicin, 5-fluorouracil, and trastuzumab, all of which are very potent anticancer drugs, are known to cause cardiotoxicity. When it comes to lowering cardiotoxicity and alleviating the harmful effects of chemotherapy medications, nanomedicine has the potential to transport therapeutic molecules. Nanotheranostics offers novel options for identifying and treating cardiotoxicity resulting from a wide range of substances, including anticancer medications. Additionally, theranostics platforms such as micellar systems, carbon-based nanomedicine, solid lipid nanoparticles, polymeric nanoparticles, and liposomes can transport chemotherapeutic medications while minimising their cardiotoxicity. The present level of understanding of the molecular and cellular processes that lead to cardiotoxicity in reaction to both traditional chemotherapy and targeted drug delivery systems is summarised in this article. This review delves into nanomedicine and nanotheranostics, with an emphasis on reducing anticancer medication-induced cardiac toxicity. Nanotheranostics provide potential solutions for early diagnosis and tailored therapy of heart injury by combining diagnostic and therapeutic capabilities into nanomedicine.
Insights
Cardiotoxicity from cancer drugs is a serious concern. Nanomedicine and nanotheranostics show promise in diagnosing and treating chemotherapy-induced heart damage, offering new therapeutic strategies.
Area of Science:
- Oncology
- Cardiology
- Nanomedicine
Background:
- Cardiotoxicity is a significant cause of mortality in cancer patients, often linked to anticancer drugs.
- Anticancer agents like doxorubicin, 5-fluorouracil, and trastuzumab can induce cardiac dysfunction, including heart failure.
- The mechanisms underlying drug-induced cardiotoxicity require further elucidation.
Purpose of the Study:
- To review the current understanding of molecular and cellular mechanisms of cardiotoxicity induced by chemotherapy and targeted delivery systems.
- To explore the potential of nanomedicine and nanotheranostics in mitigating anticancer drug-induced cardiotoxicity.
- To highlight nanotheranostics as a dual-purpose approach for early diagnosis and targeted treatment of cardiac injury.
Main Methods:
- Literature review of studies on cardiotoxicity mechanisms.
- Analysis of nanomedicine and nanotheranostics applications in cancer therapy.
- Examination of various nanocarrier systems (e.g., liposomes, nanoparticles) for drug delivery.
Main Results:
- Nanomedicine offers potential for targeted drug delivery, minimizing systemic exposure and cardiac side effects.
- Nanotheranostic platforms can integrate diagnostic and therapeutic functions for personalized treatment.
- Various nanocarrier systems demonstrate efficacy in delivering chemotherapeutics while reducing cardiotoxicity.
Conclusions:
- Nanomedicine and nanotheranostics represent promising strategies for managing and preventing cardiotoxicity in cancer patients.
- Early diagnosis and tailored therapy of cardiac injury can be achieved through integrated nanotheranostic approaches.
- Further research into nanomedicine is crucial for improving the safety and efficacy of cancer treatments.
